MHRA: UK Cobalt Chrome Modular Neck Hip Replacement Risk Advisory

• The MHRA has issued an advisory concerning increased wear and corrosion risks with certain cobalt-chrome modular neck hip replacements.
• NHS trusts and hospitals are directed to identify approximately 750 patients with specific devices from manufacturers like Aesculap, LimaCorporate, Smith & Nephew, and Stryker for clinical review.
• These affected devices, available in the UK from 2007-2019, are no longer sold, and a small number of patients may require revision surgery due to tissue reactions.
• Patients experiencing new symptoms should contact their surgeon or hospital, and report issues to the MHRA, but should expect to be contacted for assessment.
• The advisory highlights potential product liability and medical negligence risks, requiring hospitals to ensure robust patient identification and review processes.

The MHRA's advisory regarding the MHRA cobalt chrome modular neck hip replacement risk carries significant implications for both healthcare providers and the legal sector.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a significant advisory regarding an increased risk of wear and corrosion associated with specific cobalt-chrome modular neck hip replacements. This precautionary measure follows a comprehensive review by the agency, prompting a directive for NHS trusts and hospitals across the UK to identify and contact patients who have received these particular devices. The aim is to facilitate a clinical review, inform individuals of potential risks, and determine the necessity of ongoing monitoring based on their symptoms or clinical findings.

This advisory specifically targets hip replacement constructs that incorporate cobalt-chrome dual taper modular neck components from several manufacturers. Patients are advised that they should expect to be contacted directly by their implanting surgeon or hospital for an assessment as soon as feasible, rather than initiating contact themselves. However, anyone experiencing new or unexpected symptoms such as pain, stiffness, or instability related to any implant should promptly consult their surgeon or the hospital where their surgery was performed, and also report the issue to the MHRA via the Yellow Card scheme or Scotland's Incident Reporting & Investigation Centre.

The MHRA's advisory applies to devices manufactured by Aesculap AG (Metha modular), LimaCorporate (H-Max-M), Smith and Nephew (SMF), Stryker (ABG II modular), and Symbios (HARMONY modular and SPS modular). These particular cobalt-chrome modular neck hip replacements were available in the UK market between 2007 and 2019, but are no longer supplied. Current data indicates that approximately 750 patients in the UK are living with these specific implants.

While the vast majority of patients with these hip replacements experience no serious issues and have well-functioning hips, a small subset may develop problems within the tissues surrounding the hip. These complications could potentially necessitate revision surgery to address the wear and corrosion. The MHRA's review identified varying rates of revision surgery linked to metal wear across different implant systems and highlighted potential increased risks of wear and corrosion stemming from the additional interfaces inherent in these designs. These reactions in the surrounding tissue are a primary concern.

This recent action builds upon a previous MHRA review conducted in 2025, which focused on Profemur cobalt-chrome modular neck hip replacements and similarly identified elevated risks of wear, corrosion, and device fracture. Following that initial assessment, the Medicines and Healthcare products Regulatory Agency expanded its scrutiny to encompass all other cobalt-chrome dual taper modular neck hip replacement systems that had been available in the UK. Crucially, while this broader review confirmed wear and corrosion risks, it did not find evidence of a higher-than-expected rate of device fracture among the implant systems covered in this specific advisory.

The overarching conclusion from the available evidence is that all patients with these potentially affected devices warrant follow-up. Despite the estimated 750 affected patients, it is important to contextualize this within the broader landscape of over 100,000 hip replacements of all types performed annually in the UK. The MHRA's DSI/2026/010 document provides further details on the risk of metal-wear effects and the potential for revision surgery associated with these implants.

The MHRA's advisory regarding the MHRA cobalt chrome modular neck hip replacement risk carries significant implications for both healthcare providers and the legal sector. This official guidance signals a heightened potential for product liability claims against manufacturers of the Aesculap Metha modular hip, LimaCorporate H-Max-M hip, Smith Nephew SMF hip, and Stryker ABG II modular hip, among others, should patients experience complications directly attributable to the identified wear and corrosion. Furthermore, medical negligence claims could arise if healthcare providers fail to adequately identify affected patients or neglect to facilitate the mandated clinical reviews, thereby failing in their duty of care.

Law firms specializing in medical device litigation and personal injury should closely monitor developments, particularly for patients who experience adverse outcomes or are not appropriately contacted for the clinical assessments advised by the Medicines and Healthcare products Regulatory Agency advisory. For UK hospitals, compliance officers must ensure robust and auditable processes are swiftly implemented to identify all patients with these specific UK hip replacement wear corrosion devices. Proactive and thorough execution of the MHRA's recommendations is crucial to mitigate future legal exposure and ensure patient safety.

This MHRA advisory signals potential product liability and medical negligence claims in the UK. Lawyers should monitor for patients affected by these specific cobalt-chrome modular neck hip replacements who experience complications or are not appropriately contacted by healthcare providers for clinical review, as advised by the MHRA. Compliance officers in UK hospitals must ensure robust processes are in place to identify affected patients and facilitate the required clinical assessments to mitigate future legal exposure.

Source: Reporting based on a UK government health advisory.